Regent Pacific Group Limited, an investment holding company, focuses on healthcare and life sciences sectors in Europe, the United States, and the Asia Pacific. The company operates through Biopharma and Corporate Investment segments. It is involved in the research, development, manufacturing, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of AI system for the field of biological aging clocks, at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. The company also invests in listed and unlisted corporate entities. In addition, it provides management services. The company was formerly known as Endurance RP Limited and changed its name to Regent Pacific Group Limited in July 2023. Regent Pacific Group Limited was founded in 1991 and is headquartered in Central, Hong Kong.
Metrics to compare | 0575 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship0575PeersSector | |
---|---|---|---|---|
P/E Ratio | −7.9x | 2.3x | −0.5x | |
PEG Ratio | −0.09 | −0.07 | 0.00 | |
Price/Book | −6.0x | 1.4x | 2.6x | |
Price / LTM Sales | 49.1x | 1.8x | 3.3x | |
Upside (Analyst Target) | - | 45.4% | 42.8% | |
Fair Value Upside | Unlock | 23.1% | 6.5% | Unlock |